SecBot SecBot
PRESS-RELEASE ·Filed Mar 11, 2026

VACH

Voyager Acquisition Corp.
BEARISH
Impact 8/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▼ Bearish

Monitor the post-combination stock performance under the new ticker VRXA; the minimal remaining cash and tiny float suggest high volatility and limited institutional interest. Consider this a de facto reverse merger with minimal proceeds, typical of failed SPACs.

DirectionBearish
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
VACH ▼ -19.93% at T+60d
SHORT call ✓ call won +19.93% · α vs SPY +31.46% · entry $12.19 → $9.76
Entry = T+0 close
Mar 11, 2026
via day close
T+1d
-9.76%
call +9.76% · α +8.28%
$11.00
settled 8mo ago
T+5d
+2.38%
call -2.38% · α -4.57%
$12.48
settled 7mo ago
T+20d
+4.68%
call -4.68% · α -4.15%
$12.76
settled 7mo ago
T+60d
-19.93%
call +19.93% · α +31.46%
$9.76
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Voyager Acquisition Corp. completed its business combination with VERAXA Biotech AG, but approximately 99.67% of public shareholders redeemed their shares, leaving only 82,685 Class A shares post-transaction and $885,556 in the trust account. The combined company will trade under the ticker 'VRXA' on Nasdaq, marking a highly dilutive outcome for remaining shareholders.

Key Financial Metrics

Deal Value
$885.6K

Key Facts

  • 25,217,315 Class A shares were redeemed, representing 99.67% of outstanding public shares
  • Only 82,685 Class A shares remain post-redemption and will convert into shares of VERAXA Biotech Holding AG
  • Approximately $885,556 remains in the trust account after redemptions
  • The combined company will be publicly traded under the new ticker 'VRXA' on Nasdaq
  • This level of redemption indicates extreme lack of confidence from public investors

Financial Impact

Massive shareholder dilution; trust value reduced from ~$252M (assuming $10/share) to $885,556 — a 99.65% reduction in available capital

cash reservesdilutionshare countpublic float

Risk Factors

  • Extremely low cash resources may impair VERAXA's ability to fund operations or clinical development
  • Tiny public float could lead to illiquidity and extreme price volatility
  • Market perception of a 'failed' SPAC may damage investor confidence

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3253575
2 reports for VACH
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VACH — sortable, filterable
TypeNow
Mar 13, 2026
32w ago
Press Release
BEARISH ★ 8/10
$10.74 $12.90▼ −20.11%▼ −8.50%—
Mar 11, 2026
32w ago
Press Release
BEARISH ★ 8/10
$12.19 $9.76▲ +19.93%▲ +31.46%—
Showing 2 of 2

US Market Status

Market Open — Closes in 4h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026